Drug guidance
Fruquintinib for previously treated metastatic colorectal cancer
Condition
Cancer
Gastrointestinal tract
16 September 2025
-
Published on 04 Jun 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Fruquintinib 1 mg and 5 mg capsules for treating patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy.
Funding status
Fruquintinib 1 mg and 5 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.
Fruquintinib for previously treated metastatic colorectal cancer (Updated 16 Sep 2025)